Turning a targeting -catenin/bcl9 peptide inhibitor into a gdof@au core/shell nanoflower for enhancing immune response to cancer therapy in combination with immune checkpoint inhibitors

HIGHLIGHTS

• who: Weiming You and collaborators from the Department of Tumor and Immunology in Precision Medical Institute, Western China Science and Technology General Surgery Department, Tang Du Hospital, Fourth Military Medical University, Xi`an, China have published the Article: Turning a Targeting -Catenin/Bcl9 Peptide Inhibitor into a GdOF, in the Journal: Pharmaceutics 2022, 14, x FOR PEER REVIEW of /2022/
• what: The mean of the standard deviation (SD) of three independent tests was recorded in this study, and mean standard deviation differences between groups were examined for statistical significance using GraphPad Prism, version 9.1 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.